Department of Cardiology, Asklepios Klinik St. Georg, Hamburg, Germany.
Asklepios Proresearch, Hamburg, Germany.
J Cardiovasc Electrophysiol. 2019 Aug;30(8):1207-1214. doi: 10.1111/jce.13964. Epub 2019 May 21.
Atrial fibrillation (AF) and higher grade mitral valve regurgitation are often associated. For both, there are interventional therapeutic options such as pulmonary vein isolation (PVI) and percutaneous mitral valve repair (PMVR) using MitraClip.
This study investigated the feasibility, safety and clinical outcome of AF ablation in patients with prior PMVR.
This study included patients with symptomatic AF who underwent PVI after prior PMVR at a tertiary care center (14 consecutive patients, group I). A propensity-score matched group of 42 patients (1:3 matching, group II) without prior valve repair acted as controls.
Acute PVI was achieved in all patients. No difference was found regarding median procedure time (group I: 125.0 [Q1: 120.0; Q3: 176.3] vs group II: 135.0 [120.0; 177.5] minutes; P = 0.87) and median fluoroscopy duration (group I: 17.2 [12.9; 25.9] vs group II: 18.6 [12.3; 25.9] minutes; P = 0.95). In group I, one patient suffered a postprocedural transient ischemic attack. No further major complications occurred (P = 0.25). No periprocedural interference with the MitraClip was noted. The Kaplan-Meier estimate 18-month overall arrhythmia-free survival after the index procedure including a 3-month blanking period was 64.8% (95% confidence interval [CI] 42.1-99.8%) for the study group and 68.3% (95% CI, 54.6-85.6%) for the control group P = 0.35). A higher percentage of left atrial tachycardias was observed in the study group (67% vs 12% of patients with any arrhythmia recurrence; P = 0.01).
Catheter ablation of AF in patients with prior PMVR is feasible and safe and results in satisfying clinical outcome.
心房颤动(AF)和二尖瓣反流程度较高通常相关。对于两者,都有介入治疗选择,如肺静脉隔离(PVI)和使用 MitraClip 的经皮二尖瓣修复(PMVR)。
本研究旨在探讨既往行 PMVR 患者行 AF 消融术的可行性、安全性和临床转归。
本研究纳入了在三级医疗中心行 PVI 治疗的有症状性 AF 且既往行 PMVR 的患者(连续 14 例患者,组 I)。选择了 42 例无既往瓣膜修复的患者(1:3 匹配,组 II)作为对照组。
所有患者均成功实现了急性 PVI。两组间的中位手术时间(组 I:125.0[Q1:120.0;Q3:176.3] vs 组 II:135.0[120.0;177.5]min;P=0.87)和中位透视时间(组 I:17.2[12.9;25.9] vs 组 II:18.6[12.3;25.9]min;P=0.95)均无差异。组 I 中有 1 例患者术后出现短暂性脑缺血发作。无其他重大并发症发生(P=0.25)。术中未发现 MitraClip 受影响。包括 3 个月空白期的指数术后 18 个月时,研究组的总体心律失常无复发生存率估计值为 64.8%(95%置信区间[CI]42.1-99.8%),对照组为 68.3%(95%CI,54.6-85.6%)(P=0.35)。研究组中观察到更多的左房性心动过速(67% vs 任何心律失常复发患者的 12%;P=0.01)。
在既往行 PMVR 的患者中行 AF 消融术是可行且安全的,并获得了令人满意的临床转归。